The tests, revealed at the 2021 American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Lab Expo in Atlanta, could improve screening rates for colorectal and prostate cancers, since studies show many patients avoid colonoscopies and prostate exams because they’re invasive.
The blood test for colorectal cancer is more accurate than routine stool occult blood tests, researchers said.
The saliva test distinguishes between prostate cancer and benign prostate enlargement by testing for eight different microRNAs that either support or suppress tumor growth.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.